Tratamiento de linfomas no Hodgkin de mal pronóstico y linfomas no clasificados de alto grado con dosis intensivas altas de quimioterapia combinada durante ocho semanas (Protocolo de Vanderbilt)

Insuasty Enriquez, Jesús Solier.
Bogotá, D.C; s.n; ago. 1995. 98 p. tab.
Tesis en Español | LILACS | ID: lil-190276

Documentos relacionados

  1. Allogeneic stem cell transplant in non-Hodgkin lymphomas: Still an indication?
  2. Therapeutic challenges in primary CNS lymphoma.
  3. Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update.
  4. Late effects and frontline treatment selection for children with non-Hodgkin lymphoma.
  5. Supervivencia de los pacientes con linfoma no Hodgkin difuso B de células grandes
  6. The forgotten survivor: A comprehensive review on Non-Hodgkin lymphoma survivorship.
  7. Allogeneic stem cell transplantation and CAR-T in B-cell Non-Hodgkin Lymphoma: a two-center experience and review of the literature.
  8. Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens.
  9. Children's Oncology Group's 2023 blueprint for research: Non-Hodgkin lymphoma.
  10. Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study.